Celia Eckert Sells 3,244 Shares of Xencor (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the sale, the senior vice president directly owned 78,685 shares of the company’s stock, valued at $885,206.25. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Celia Eckert also recently made the following trade(s):

• On Friday, March 6th, Celia Eckert sold 1,767 shares of Xencor stock. The shares were sold at an average price of $11.02, for a total value of $19,472.34.
• On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The stock was sold at an average price of $11.90, for a total value of $17,754.80.

Xencor Stock Performance

Shares of Xencor stock traded up $0.55 during trading on Monday, hitting $11.87. 835,908 shares of the company’s stock traded hands, compared to its average volume of 711,120. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69. The business has a 50-day simple moving average of $12.79 and a 200-day simple moving average of $13.00. The stock has a market capitalization of $870.55 million, a P/E ratio of -9.57 and a beta of 0.95. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.25 and a quick ratio of 6.25.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The firm had revenue of $28.24 million for the quarter, compared to the consensus estimate of $29.97 million. During the same quarter last year, the firm posted ($0.62) EPS. The business’s quarterly revenue was down 46.6% compared to the same quarter last year. As a group, analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Walleye Capital LLC purchased a new stake in Xencor during the second quarter valued at approximately $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Xencor by 153.2% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 17,773 shares during the period. Squarepoint Ops LLC lifted its position in Xencor by 3,150.0% in the second quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock worth $2,854,000 after buying an additional 351,979 shares during the last quarter. SG Americas Securities LLC purchased a new position in Xencor during the third quarter worth $1,062,000. Finally, Panagora Asset Management Inc. increased its position in Xencor by 68.4% during the second quarter. Panagora Asset Management Inc. now owns 488,892 shares of the biopharmaceutical company’s stock valued at $3,843,000 after acquiring an additional 198,564 shares during the last quarter.

Analyst Ratings Changes

XNCR has been the topic of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Truist Financial assumed coverage on shares of Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 target price for the company. Barclays lifted their price objective on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.